Financial Performance - The company's operating revenue for the third quarter was CNY 128,153,090.70, a decrease of 49.03% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 17,874,633.27, representing a decrease of 66.14% year-on-year[4] - The net profit after deducting non-recurring gains and losses was a loss of CNY 21,955,970.95, a decrease of 72.82% year-on-year[4] - Year-to-date operating revenue decreased by 35.84%, primarily due to a decline in product prices[9] - Net profit attributable to shareholders decreased by 66.14% year-to-date, impacted by ongoing investments in R&D[9] - Net profit excluding non-recurring gains and losses decreased by 72.82% year-to-date, reflecting a significant drop in operating income[9] - The net profit for Q3 2024 was CNY 61,008,648.47, a decrease of 66.16% compared to CNY 180,480,568.79 in Q3 2023[24] - The total profit for Q3 2024 was CNY 66,164,634.16, down 66.19% from CNY 195,883,102.35 in the same period last year[24] - The operating profit for Q3 2024 was CNY 65,450,654.17, a decline of 66.66% from CNY 195,933,021.66 in Q3 2023[24] Research and Development - The R&D investment totaled CNY 32,016,993.64, accounting for 24.98% of operating revenue, an increase of 9.00 percentage points compared to the previous year[5] - Research and development expenses for the first three quarters of 2024 amounted to CNY 99,676,406.70, compared to CNY 114,743,907.65 in 2023, reflecting a decrease of approximately 13.1%[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,494,818,114.71, a decrease of 4.24% from the end of the previous year[5] - The company's total assets as of the end of the third quarter of 2024 were CNY 3,494,818,114.71, down from CNY 3,649,560,924.88 at the end of the same period in 2023, a decline of about 4.2%[22] - Total liabilities as of the end of the third quarter of 2024 were CNY 698,382,450.68, compared to CNY 770,325,491.93 in 2023, representing a decrease of approximately 9.3%[20] - The company's total equity as of the end of the third quarter of 2024 was CNY 2,796,435,664.03, down from CNY 2,879,235,432.95 in 2023, indicating a decline of about 2.9%[22] Cash Flow - The net cash flow from operating activities was reported as not applicable for the current period, with a cumulative cash flow of -CNY 17,279,413.75 year-to-date[4] - The cash flow from operating activities for the first three quarters of 2024 was CNY 739,551,633.47, down 19.0% from CNY 913,078,524.92 in the same period of 2023[26] - The net cash flow from investing activities for Q3 2024 was CNY 50,828,134.57, compared to a negative CNY 81,534,431.39 in Q3 2023[27] - The cash and cash equivalents at the end of Q3 2024 were CNY 1,155,205,573.66, an increase from CNY 769,302,304.79 at the end of Q3 2023[27] - The company experienced a cash outflow from operating activities totaling CNY 756,831,047.22 in Q3 2024, compared to CNY 899,329,366.94 in Q3 2023[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,998[10] - The top shareholder, Shi Chunbao, holds 29.92% of the shares, totaling 114,766,497 shares[10] - The company has not reported any significant changes in shareholder participation in margin trading or stock lending activities[18] Earnings Per Share - The company’s diluted earnings per share for the quarter was -CNY 0.05, down 65.96% from CNY 0.16 in the same period last year[5] - Basic earnings per share decreased by 65.96% year-to-date, correlating with the decline in net profit[9] - Diluted earnings per share also decreased by 65.96% year-to-date, consistent with the overall profit decline[9] - Basic earnings per share for Q3 2024 were CNY 0.16, down from CNY 0.47 in Q3 2023[25] Government Subsidies and Other Income - The company received government subsidies amounting to CNY 4,645,666.67 year-to-date, which are closely related to its normal business operations[6] - The company reported a total of CNY 39,213.61 from the disposal of non-current assets, indicating some asset impairment reversals[6] - The company reported a foreign exchange gain of CNY 1,677.48 in Q3 2024, compared to a gain of CNY 673,557.68 in Q3 2023[27] Operating Costs - Total operating costs for the first three quarters of 2024 were CNY 449,469,327.29, down from CNY 607,002,161.57 in 2023, indicating a reduction of about 26%[23] - The company reported a net profit margin decline due to increased sales and management expenses, with sales expenses at CNY 163,464,944.14 compared to CNY 233,751,182.69 in 2023, a decrease of approximately 30%[23]
春立医疗(01858) - 2024 Q3 - 季度业绩